Drugs / Gosogliptin
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00596518 | Oct 2007 → Jul 2008 | chronic kidney disease | Pfizer | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00618007 | Feb → Aug 2008 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00473525 | Jul 2007 → Jun 2008 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03088670 | Apr 2013 → Mar 2014 | type 2 diabetes mellitus | SatRx LLC | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gosogliptin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03088670 ↗ |
| Known as | Gosogliptina | ChEMBL registry synonym — accepted as the source's own label CHEMBL515387 ↗ |
| Known as | Gosogliptine | ChEMBL registry synonym — accepted as the source's own label CHEMBL515387 ↗ |
| Known as | PF-00734200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00473525 ↗ |
| Known as | PF-734,200 | ChEMBL registry synonym — accepted as the source's own label CHEMBL515387 ↗ |
| Action | Inhibit | “Dipeptidyl peptidase IV inhibitor” CHEMBL515387 ↗ |
| Modality | Small molecule | — CHEMBL515387 ↗ |
| Route | Oral | “following oral administration” NCT00473525 ↗ |
| Target | DPP4 | “Dipeptidyl peptidase IV inhibitor” CHEMBL515387 ↗ |